跳至主要内容
临床试验/NCT04695522
NCT04695522Unknown1 期

Phase I Trial of ADR-002K for Patients With Ischemic Cardiomyopathy Who Undergo Coronary Artery Bypass Surgery

Osaka University2 个研究点 分布在 1 个国家目标入组 6 人开始时间: 2019年11月27日最近更新:
适应症

试验速览

阶段
1 期
入组人数
6
试验地点
2
主要终点
Number of complication associated with drug administration method

研究概览

简要总结

Ischemic cardiomyopathy undergoing coronary artery bypass surgery

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

入排标准

年龄范围
20 Years 至 80 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patients who are clinically diagnosed with ischemic cardiomyopathy and receive CABG
  • Patients with a left ventricular ejection fraction of 40% or less by cardiac ultrasonography within 4 weeks before obtaining consent

排除标准

  • Patients who have a combination of cardiovascular disease such as severe organic valvular disease or aortic aneurysm determined by investigator or co-investigator to affect clinical trial procedure
  • Patients whose participation in a clinical trial is considered inappropriate at the discretion of the investigator or co-investigator

结局指标

主要结局

Number of complication associated with drug administration method

时间窗: 26 weeks

Feasibility of drug administration method

Amount of change in late gadolinium contrast-enhanced area at the time of screening and 6 months after surgery

时间窗: 26 weeks

Efficacy (Exploratory)

Number of participants with Adverse event

时间窗: 26 weeks

Safety assessment related to adverse events and this product

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Daisuke Mori

Assistant professor

Osaka University

研究点 (2)

Loading locations...

相似试验